ArticleJournal of diabetes science and technology2013
Gel encapsulation of glucose nanosensors for prolonged in vivo lifetime.
Article in Journal of diabetes science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Optical Nanosensors forAnalytical methods : advancing methods and applications · 2020Article
- In Vivo Biosensing: Progress and Perspectives.ACS sensors · 2017Article
- Glucose-sensitive nanofiber scaffolds with an improved sensing design for physiological conditions.The Analyst · 2015Article
- Implantable nanosensors: toward continuous physiologic monitoring.Analytical chemistry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundFluorescent glucose-sensitive nanosensors have previously been used in vivo to track glucose concentration changes in interstitial fluid. However, this technology was limited because of loss of fluorescence intensity due to particle diffusion from the injection site. In this study, we encapsulated the nanosensors into injectable gels to mitigate nanosensor migration in vivo.
methodsGlucose-sensitive nanosensors were encapsulated in two different commercially available gelling agents: gel 1 and gel 2. Multiple formulations of each gel were assessed in vitro for their nanosensor encapsulation efficiency, permeability to glucose, and nanosensor retention over time. The optimal formulation for each gel, as determined from the in vitro assessment, was then tested in mice, and the lifetime of the encapsulated nanosensors was compared with controls of nanosensors without gel.
resultsFive gel formulations had encapsulation efficiencies of the nanosensors greater than 90%. Additionally, they retained up to 20% and 40% of the nanosensors over 24 h for gel 1 and gel 2, respectively. In vivo, both gels prevented diffusion of glucose nanosensors at least three times greater than the controls.
conclusionsEncapsulating glucose nanosensors in two injectable gels prolonged nanosensor lifetime in vivo; however, the lifetime must still be increased further to be applicable for diabetes monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.